Form 4: Aadi Bioscience CFO Awarded Stock Options and Restricted Stock Units
SEC Form 4 Filing
A Form 4 filing reveals that Aadi Bioscience's CFO, Scott M. Giacobello, was granted stock options and restricted stock units on March 1, 2024.
Summary
- Scott M. Giacobello, the CFO of Aadi Bioscience, Inc., received stock options and restricted stock units (RSUs) on March 1, 2024.
- He was granted options to purchase 138,263 shares at an exercise price of $1.92, which vest immediately.
- An additional 55,000 stock options were granted, vesting over four years from March 1, 2024.
- He also received 27,000 RSUs, which vest in equal installments over four years from March 1, 2024.
- The grants are subject to his continued service with Aadi Bioscience, Inc.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive.
Positives
- The immediate vesting of options for 138,263 shares could be seen as a strong incentive for the CFO.
- The vesting schedules for the additional options and RSUs align the CFO's interests with the long-term performance of the company.
Industry Context
Equity compensation is a common practice in the biotechnology industry to attract and retain key executives. The vesting schedules are designed to incentivize long-term commitment and performance.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Vesting schedules, such as the four-year vesting described in the document, are typical to align executive incentives with long-term company performance.
- Companies like Amgen, Gilead, and Biogen also utilize stock options and RSUs as part of their executive compensation plans.
Stakeholder Impact
- The equity grants could positively impact shareholder value if the CFO's performance leads to increased company success.
- The grants incentivize the CFO to make decisions that benefit the company's long-term growth.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of earliest transaction (grant date for stock options and RSUs) |
| 03/01/2034 | Expiration date for stock options |
| 03/04/2024 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.